Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06221969 · ClinicalTrials.gov registry record · Phase 3
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor
A Phase 3 study of Type 2 Diabetes, sponsored by Novo Nordisk A/S.
- Active
- Registry status
- Phase 3
- Development phase
- 1,000
- Enrollment target
- 20
- Study locations
NCT06221969: Active Phase 3 study of Type 2 Diabetes, sponsored by Novo Nordisk A/S.
NCT06221969 is a Phase 3 study of Type 2 Diabetes that is active but no longer recruiting, run by Novo Nordisk A/S. The registered enrollment target is 1,000 participants, below the 3,921-participant average among 327 other Type 2 Diabetes trials with a reported enrollment target (74% lower). The trial reports 20 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06221969, a Phase 3 study of Type 2 Diabetes, is active but no longer recruiting, sponsored by Novo Nordisk A/S.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 1,000 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will look at how well CagriSema helps people with type 2 diabetes lower their blood sugar and body weight. CagriSema is a new investigational medicine. Doctors may not yet prescribe CagriSema. CagriSema will be compared to a medicine called tirzepatide that doctors may prescribe in some countries. Participants will get either CagriSema or tirzepatide. Which treatment participant get is decided by chance like flipping a coin. Participant will have an equal chance of receiving either drug. For each participant, the study will last for up to one and a half years.
Primary Outcome
Measured in percentage (%)-points.
Conditions Studied
Interventions
- DRUG Tirzepatide
- DRUG Semaglutide
- DRUG Cagrilintide
Study Locations (20)
California
- Velocity Clin Res-Chula Vista - Chula Vista
- Headlands Research California, LLC - Escondido
- Neighborhood Healthcare - Escondido
- St. Jude Heritage Yorba Linda - Pediatric Ste D - Fullerton
- Diabetes & Endocrine Specialists - La Mesa - La Mesa
- Diabetes and Endocrine Specialists - La Mesa - La Mesa
- Velocity Clin Res San Diego - La Mesa
- Clinical Trials Research - Lincoln
- Loma Linda Univ Hlth Cr Endo - Loma Linda
- Valley Clinical Trials, Inc. - Northridge
- Desert Oasis Healthcare - Palm Springs
- Velocity Clin Res - Panorama - Panorama City
- Western University of Health Sciences - Pomona
Arizona
- Prime Medical Group, LLC - Gilbert
- Velocity Clinical Research-Phoenix - Phoenix
- Synexus Rsch /Cnt Phnx Med C - Phoenix
Alabama
- Synexus Clin Res-Birmingham - Birmingham
- Univ of Alabama_Birmingham - Birmingham
Arkansas
- Arkansas Clinical Research - Little Rock
- Unity Health-Searcy Medical Center - Searcy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,000 participants |
| Start Date | 2024-01-16 |
| Est. Completion | 2026-04-03 |
| Phase | Phase 3 |
What the registry record for NCT06221969 still lists
NCT06221969 is an interventional study that assigns participants to a tested intervention. Its 1,000 participants enrollment target places it among the larger protocols in the corpus, below the 3,921-participant average among 327 other Type 2 Diabetes trials with a reported enrollment target (74% lower).
The record links to 1 condition, with Type 2 Diabetes appearing as the primary indexed condition, and to 3 interventions - of which Tirzepatide is the first listed.
NCT06221969 names 20 study sites across 4 states, led by California, Arizona, Alabama.
Frequently Asked Questions
What is clinical trial NCT06221969 about?
NCT06221969 is a clinical study titled "A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor". This study will look at how well CagriSema helps people with type 2 diabetes lower their blood sugar and body weight. CagriSema is a new investigational medicine. Doctors may not yet prescribe CagriSema. CagriSema will be compared to a medicine called tirzepatide that doctors may prescribe in some c...
What is the current status of trial NCT06221969?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 1,000 participants. The study started on 2024-01-16. Estimated completion is 2026-04-03.
What conditions does trial NCT06221969 study?
This clinical trial studies the following conditions: Type 2 Diabetes.
What interventions are being tested in trial NCT06221969?
The interventions under investigation include: Tirzepatide (DRUG), Semaglutide (DRUG), Cagrilintide (DRUG).
Who is sponsoring clinical trial NCT06221969?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06221969 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 2 Diabetes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06221969's enrollment target sits among peer trials
1,000 24th of 327 higher than 302 of 327 other Type 2 Diabetes trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Type 2 Diabetes trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes
RECRUITING · Phase 3
-
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes
RECRUITING · Phase 3
-
A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS)
RECRUITING · Phase 3
-
Effects of Modulators of Gluconeogenesis, Glycogenolysis and Glucokinase Activity
ACTIVE NOT RECRUITING · Phase 3
-
Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)
ACTIVE NOT RECRUITING · Phase 3
-
Weight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00018044 · 1,000 participants
Study of Mycobacterial Infections
- NCT01036581 · 1,000 participants · NA
Advanced Functional and Structural MRI Techniques for Neuropharmacological Imaging
- NCT01192048 · 1,000 participants
Genetics of Congenital Heart Disease
- NCT01553214 · 1,000 participants · Phase 4
Improving White Blood Cell Collection From Healthy Donors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI